-
盛德动态
CMS Sets Stage for 2028 Medicare Drug Price Negotiations — First Look at Negotiations for Part B
May 21, 2025
Global Life Sciences Update
-
盛德动态
Drug Pricing Executive Order Aims to End Inflation Reduction Act “Pill Penalty,” Resurrect Policies From First Trump Administration
April 17, 2025
Global Life Sciences Update
-
盛德动态
Medicare Part D’s New Cost-Smoothing Program: Key Insights and Impacts
September 17, 2024
Healthcare Update
-
盛德动态
Inflation Reduction Act: CMS Releases New “Medicare Drug Price Negotiation Program” Guidance as Industry Lawsuits Mount
July 14, 2023
Global Life Sciences Update
-
博客
Impact Of Inflation Reduction Act On Drug Development For U.S. Market
May 23, 2023
GoodLifeSci
-
盛德动态
HHS Faces IRA Implementation Risk Without Notice and Comment
April 3, 2023
Global Life Sciences Update
-
盛德动态
Inflation Reduction Act: CMS Solicits Comments on Price Negotiation Program Guidance, Makes Part B Coinsurance Announcements
March 20, 2023
Global Life Sciences Update
-
盛德动态
U.S. Inflation Reduction Act Implementation: Public Opportunities to Comment on New Medicare Inflation Rebates Program
February 17, 2023
Global Life Sciences Update
-
盛德动态
Inflation Reduction Act Implementation: Serious Hurdles to Accurately Calculating Medicare Part B Inflation Rebates
February 14, 2023
Global Life Sciences Update
-
盛德动态
Inflation Reduction Act Implementation: Public Input Opportunities Related to U.S. Medicare Drug Price Negotiation Program
February 3, 2023
Global Life Sciences Update
-
盛德动态
Unprecedented Changes to Medicare Programs Leave Many Questions Unanswered for Pharmaceutical Manufacturers
August 29, 2022
Global Life Sciences Update
